[ad_1] While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. The central bank has held rates steady since last July as it patiently waits for more signs that inflation is cooling. But a…
[ad_1] Shortly after the opening bell, we will be buying 140 shares of Abbott Laboratories at roughly $112. Following the trade, Jim Cramer’s Charitable Trust will own 700 shares of ABT, increasing our weighting in the portfolio to 2.42% from 1.95%. We are buying more Abbott Laboratories into its recent weakness as we continue to…
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Markets rebound as Nvidia goes…
[ad_1] CNBC’s Jim Cramer said Tuesday that Elon Musk’s disclosure that he takes prescription ketamine for depression was courageous and “saved a lot of people from killing themselves.” “I defend him as much as possible because there are many people who would never be brave enough to admit they take this drug,” Cramer said on…
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Markets bounce : Stocks kicked…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. U.S. stocks jumped Monday as the Nasdaq and S & P 500 attempts to recover from back-to-back weekly losses. Major gains were seen in tech stocks to start the…
[ad_1] There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. U.S. stocks were mixed Wednesday following Tuesday’s record high close for the S & P 500 on a rebound in the artificial intelligence momentum trade. One day later, tech…
[ad_1] Jonathan Raa | Nurphoto | Getty Images Novo Nordisk shares climbed 7% on Thursday, hitting a fresh record high after the Danish pharmaceutical giant reported positive early trial data for a new experimental weight loss drug. The company told an investor meeting that the Phase I trial of its highly-anticipated obesity drug amycretin showed…
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Inflation relief: The stock market…
